This broad, high-level report analyzes the
expanding Personalized Medicine market. This world market includes
important core medical product areas that
will continue to have a powerful impact on current and future healthcare
delivery. This business report examines key market segments such as targeted
drugs and key personalized medicine diagnostics, including companion diagnostic
IVDs, LDTs, diagnostic services and related tools or technologies.
Many people already know about DNA, genes and the human genome. The science driving personalized medicine includes pharmacogenetics, pharmacoproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test). The companion diagnostic identifies which patients would likely benefit from a particular therapy or those who might suffer from a bad side effect. The test information enables doctors to select the drug therapy that would benefit the patient. Drug developers in clinical trials could use a companion diagnostic to select patents that would benefit from a targeted drug.
The report discusses important technologies, including microarray, next-generation sequencing, PCR, bioinformatics, nanotechnology and other platforms. This section highlights key platforms and selected vendors. For example, the field of clinical next generation sequencing is expected to have an impact on personalized medicine.
Many people already know about DNA, genes and the human genome. The science driving personalized medicine includes pharmacogenetics, pharmacoproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test). The companion diagnostic identifies which patients would likely benefit from a particular therapy or those who might suffer from a bad side effect. The test information enables doctors to select the drug therapy that would benefit the patient. Drug developers in clinical trials could use a companion diagnostic to select patents that would benefit from a targeted drug.
The report discusses important technologies, including microarray, next-generation sequencing, PCR, bioinformatics, nanotechnology and other platforms. This section highlights key platforms and selected vendors. For example, the field of clinical next generation sequencing is expected to have an impact on personalized medicine.
Trends in Personalized Medicine
Report Details:
Published: April 2012
No. of Pages: 171
Price: Single
User License – US$2895 Corporate User License – US$6995
The report covers subjects including
important personalized medicine concepts. The study discusses key biomarkers,
commercial diagnostics and therapeutics that drive personalized medicine.
The study highlights new personalized diagnostics. This research examines the
current targeted therapeutics on the market and drugs in the clinical
pipeline.
The report highlights major government regulatory activities that involve personalized medicine in the US and Europe. The US FDA and the European EMA have drafted guidance papers to help drug makers and diagnostic firms develop future targeted therapies guided by companion diagnostics. The recent FDA approvals of Pfizer’s Xalkori for lung cancer and Roche’s Zelboraf for melanoma demonstrate that a surge in new targeted drugs is happening.
This study discusses important personalized medicine topics and provides the reader with key findings. The report estimates that the world personalized medicine market value will reach multi-billions of dollars in 2012, with a strong double-digit growth rate. This study reviews the activities of 31 companies.
The report highlights major government regulatory activities that involve personalized medicine in the US and Europe. The US FDA and the European EMA have drafted guidance papers to help drug makers and diagnostic firms develop future targeted therapies guided by companion diagnostics. The recent FDA approvals of Pfizer’s Xalkori for lung cancer and Roche’s Zelboraf for melanoma demonstrate that a surge in new targeted drugs is happening.
This study discusses important personalized medicine topics and provides the reader with key findings. The report estimates that the world personalized medicine market value will reach multi-billions of dollars in 2012, with a strong double-digit growth rate. This study reviews the activities of 31 companies.
Request a Sample for or Inquire before buying the report @
No comments:
Post a Comment